Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Homo sapiens | v-ets avian erythroblastosis virus E26 oncogene homolog | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | Fli-1 protein | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Loa Loa (eye worm) | fli-1 protein | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Schistosoma mansoni | ets-related | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Schistosoma japonicum | ko:K09435 transcriptional regulator ERG, putative | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0136 | 0.2416 | 0.2031 |
Brugia malayi | Ets-domain containing protein | 0.0087 | 0.0506 | 0.0506 |
Brugia malayi | Ets-domain containing protein | 0.0087 | 0.0506 | 0.0506 |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.0223 | 0.5842 | 0.5621 |
Loa Loa (eye worm) | hypothetical protein | 0.0075 | 0.0006 | 0.0006 |
Schistosoma mansoni | ets-related | 0.0265 | 0.7528 | 0.7403 |
Brugia malayi | Matrixin family protein | 0.0148 | 0.2899 | 0.2899 |
Brugia malayi | Fli-1 protein | 0.0265 | 0.7528 | 0.7528 |
Brugia malayi | Hemopexin family protein | 0.0087 | 0.0483 | 0.0483 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.0223 | 0.5842 | 0.5621 |
Onchocerca volvulus | Matrilysin homolog | 0.0136 | 0.2416 | 0.2031 |
Loa Loa (eye worm) | matrixin family protein | 0.0136 | 0.2416 | 0.2416 |
Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.0087 | 0.0506 | 0.0506 |
Brugia malayi | MH2 domain containing protein | 0.0235 | 0.6342 | 0.6342 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0235 | 0.6342 | 0.6342 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0235 | 0.6342 | 0.6342 |
Loa Loa (eye worm) | matrixin family protein | 0.0148 | 0.2899 | 0.2899 |
Loa Loa (eye worm) | fli-1 protein | 0.0265 | 0.7528 | 0.7528 |
Schistosoma mansoni | gabp alpha | 0.0087 | 0.0506 | 0.0024 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 143.2 uM | Cytotoxicity against human MT2 cells after 4 days by XTT assay | ChEMBL. | 19053778 |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 47.7548 uM | PubChem BioAssay. qHTS Assay for the Inhibitors of FEN1: Confirmatory Assay for Cherry-picked Compounds. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Kappa. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588638] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.